Elizabeth Plimack, MD, MS, FASCO

Elizabeth Plimack, MD, MS, FASCO, is the Deputy Director of Fox Chase Cancer Center.

Articles by Elizabeth Plimack, MD, MS, FASCO

Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | September 10, 2024
Dr. Plimack provides an update on the SWOG S1314 trial for MIBC, including four genes predictive of pT0 disease after NAC.
View More
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel discussed important takeaways from RCC studies presented at ASCO GU.
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel shifts to focus on the current state of non-clear cell kidney cancer.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. McDermott advocates for immune therapy in frontline RCC care.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
Elizabeth Plimack, MD, MS, FASCOAdvanced Renal Cell Carcinoma | May 1, 2024
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Elizabeth Plimack, MD, MS, FASCOAdvanced Urothelial Carcinoma | December 19, 2023
Dr. Plimack provides a summary of her presentation at the SUO Annual Meeting on the progress of ADCs in UC research.
Brian Rini, MD, FASCOVideo Insights | August 23, 2023
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
Brian Rini, MD, FASCOVideo Insights | August 23, 2023
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Brian Rini, MD, FASCOVideo Insights | August 1, 2023
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
Elizabeth Plimack, MD, MS, FASCOAdvanced Urothelial Carcinoma | April 24, 2023
Dr. Plimack discusses the results of her phase 2 study on hypomethylating agents, and gives a preview of research to come.
Elizabeth Plimack, MD, MS, FASCOAdvanced Urothelial Carcinoma | April 24, 2023
Elizabeth Plimack, MD, MS, provides an overview of a recent phase 2 trial of guadecitabine plus atezolizumab for mUC.